A. Creanga

This study shows that co-immunization with stem immunogens from group 1 and 2 influenza A HAs elicits cross-group neutralizing antibodies and protective immunity in multiple animal models.

This paper identifies an antibody, WS6, from a mouse immunized with SARS-CoV-2 spike mRNA, which neutralizes diverse beta-coronaviruses by targeting a conserved helical epitope on the S2 subunit.

The paper identifies potent monoclonal antibodies that neutralize the B.1.1.529 SARS-CoV-2 variant and reveals structural mechanisms enabling their effectiveness.

This study designs stabilized recombinant influenza neuraminidase tetramers by uncovering structural principles and improving thermal stability and antibody affinity.

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

This study identifies a CCR2-dependent monocyte-derived cell mechanism that restricts SARS-CoV-2 infection and inflammation in the lungs of mice.

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

The paper introduces a Neutralization Landscape to analyze antibody-virus interactions and decompose antibody mixtures targeting influenza hemagglutinin stem proteins.

Nanoparticle immunogens with four seasonal influenza hemagglutinins elicit neutralizing antibodies against both the head and stem, providing broad protection against diverse influenza strains.

The paper develops a fluorescent reporter virus panel to enable high-throughput neutralization profiling of influenza antibodies without requiring high-containment labs.